These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
27. CSF neurotensin concentrations and antipsychotic treatment in schizophrenia and schizoaffective disorder. Sharma RP; Janicak PG; Bissette G; Nemeroff CB Am J Psychiatry; 1997 Jul; 154(7):1019-21. PubMed ID: 9210757 [TBL] [Abstract][Full Text] [Related]
28. Monoamine metabolite levels in cerebrospinal fluid and brain atrophy in lobotomized schizophrenic patients. Rimón R; Roos BE; Kampman R; Hyyppä S; Ranta P; Myllylä V Ann Clin Res; 1979 Feb; 11(1):25-9. PubMed ID: 453776 [TBL] [Abstract][Full Text] [Related]
29. [Changes in the CSF levels of monoamine metabolites in 102 chronic schizophrenic patients following probenecid before and after neuroleptic medication]. Chen YF Zhonghua Shen Jing Jing Shen Ke Za Zhi; 1984 Oct; 17(5):273-7. PubMed ID: 6085683 [No Abstract] [Full Text] [Related]
31. No major influence of regular tobacco smoking on cerebrospinal fluid monoamine metabolite concentrations in patients with psychotic disorder and healthy individuals. Hjärpe J; Söderman E; Andreou D; Sedvall GC; Agartz I; Jönsson EG Psychiatry Res; 2018 May; 263():30-34. PubMed ID: 29482043 [TBL] [Abstract][Full Text] [Related]
32. Clonidine treatment of schizophrenia: can we predict treatment response? van Kammen DP; Peters JL; van Kammen WB; Rosen J; Yao JK; McAdam D; Linnoila M Psychiatry Res; 1989 Mar; 27(3):297-311. PubMed ID: 2469097 [TBL] [Abstract][Full Text] [Related]
33. Reliability of norepinephrine and major monoamine metabolite measurements in CSF of schizophrenic patients. Linnoila M; Ninan PT; Scheinin M; Waters RN; Chang WH; Bartko J; van Kammen DP Arch Gen Psychiatry; 1983 Dec; 40(12):1290-4. PubMed ID: 6197036 [TBL] [Abstract][Full Text] [Related]
34. Cerebrospinal fluid amine metabolites in acute schizophrenia. Post RM; Fink E; Carpenter WT; Goodwin FK Arch Gen Psychiatry; 1975 Aug; 32(8):1063-9. PubMed ID: 1156113 [TBL] [Abstract][Full Text] [Related]
35. CSF amine metabolites and depression. Peabody CA; Faull KF; King RJ; Whiteford HA; Barchas JD; Berger PA Psychiatry Res; 1987 May; 21(1):1-7. PubMed ID: 2440071 [TBL] [Abstract][Full Text] [Related]
36. Cerebroventricular size and cerebrospinal fluid monoamine metabolites in schizophrenic patients and healthy volunteers. Nybäck H; Berggren BM; Hindmarsh T; Sedvall G; Wiesel FA Psychiatry Res; 1983 Aug; 9(4):301-8. PubMed ID: 6196802 [TBL] [Abstract][Full Text] [Related]
37. Effects of raclopride treatment on plasma and CSF HVA: relationships with clinical improvement in male schizophrenics. Csernansky JG; Newcomer JW; Jackson K; Lombrozo L; Faull KF; Zipursky R; Pfefferbaum A; Faustman WO Psychopharmacology (Berl); 1994 Nov; 116(3):291-6. PubMed ID: 7534423 [TBL] [Abstract][Full Text] [Related]
38. CSF levels of receptor-active endorphins in schizophrenic patients: correlations with symptomatology and monoamine metabolites. Lindström LH; Besev G; Gunne LM; Terenius L Psychiatry Res; 1986 Oct; 19(2):93-100. PubMed ID: 2431427 [TBL] [Abstract][Full Text] [Related]
39. The effect of olanzapine treatment on monoamine metabolite concentrations in the cerebrospinal fluid of schizophrenic patients. Scheepers FE; Gispen-de Wied CC; Westenberg HG; Kahn RS Neuropsychopharmacology; 2001 Oct; 25(4):468-75. PubMed ID: 11557160 [TBL] [Abstract][Full Text] [Related]
40. Relationship between abnormal brainstem auditory-evoked potentials and subnormal CSF levels of HVA and 5-HIAA in first-episode schizophrenic patients. Lindström LH; Wieselgren IM; Klockhoff I; Svedberg A Biol Psychiatry; 1990 Sep; 28(5):435-42. PubMed ID: 1698468 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]